Balversa and Indacaterol
Determining the interaction of Balversa and Indacaterol and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter, resulting in increased toxicity of these drugs. In vitro, erdafitinib has been shown to be an inhibitor of P-gp. However, no pharmacokinetic data are available from drug interaction studies. MANAGEMENT: Concomitant use of erdafitinib and P-gp substrates should generally be avoided. If concomitant use is required, administer erdafitinib at least 6 hours before or after administration of P-gp substrates with narrow therapeutic ranges. References "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.
Professional:GENERALLY AVOID: Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter, resulting in increased toxicity of these drugs. In vitro, erdafitinib has been shown to be an inhibitor of P-gp. However, no pharmacokinetic data are available from drug interaction studies.
MANAGEMENT: Concomitant use of erdafitinib and P-gp substrates should generally be avoided. If concomitant use is required, administer erdafitinib at least 6 hours before or after administration of P-gp substrates with narrow therapeutic ranges.
- "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.
Generic Name: indacaterol
Brand name: Arcapta Neohaler
Synonyms: Indacaterol (inhalation)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Balversa-Indacaterol and Glycopyrrolate
- Balversa-Indacaterol and glycopyrrolate Inhalation
- Balversa-Indacaterol inhalation
- Balversa-Indacaterol Maleate
- Balversa-Indapamide
- Balversa-Inderal
- Indacaterol-Balziva
- Indacaterol-Banophen
- Indacaterol-Banophen (Diphenhydramine (Topical))
- Indacaterol-Banophen (Diphenhydramine Capsules and Tablets)
- Indacaterol-Banzel
- Indacaterol-Banzel (Rufinamide Oral Suspension)